Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma.
Thirty patients with refractory advanced breast cancer who had no prior treatment with doxorubicin or VP-16-213 received doxorubicin 45 mg/m2 I.V. on day 1 and VP-16-213 50 mg/m2 I.V. on days 1 through 5. Courses were repeated every 21 days when hematologic recovery permitted. Among 30 evaluable patients, one had a complete response and 11 had a partial response. Four patients had stabilization of their disease. There was thus a 40% response rate with a median response duration of 146 days (range 35-540). Toxicity included moderate to severe myelosuppression, infections, hemorrhage, and mucositis. In these poor prognoses in previously treated patients, the combination of doxorubicin and VP-16-213 appears to be an effective secondary treatment for metastatic breast cancer.
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013921:Thrombocytopenia / Q000139:chemically induced
D005047:Etoposide; D004317:Doxorubicin; D011034:Podophyllotoxin